SOLICITATION NOTICE
B -- Non-Clinical Studies and Laboratory Support IDIQ_Amendment2
- Notice Date
- 3/30/2023 2:06:24 PM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- FDA OFFICE OF ACQ GRANT SVCS Beltsville MD 20705 USA
- ZIP Code
- 20705
- Solicitation Number
- FDA-RFP-75F40122R00067_Amendment2
- Response Due
- 4/5/2023 2:30:00 PM
- Archive Date
- 04/20/2023
- Point of Contact
- Nikola Zuber, Phone: 3017969671, Ian Weiss, Phone: 3017965728
- E-Mail Address
-
Nikola.Zuber@fda.hhs.gov, Ian.Weiss@fda.hhs.gov
(Nikola.Zuber@fda.hhs.gov, Ian.Weiss@fda.hhs.gov)
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with (IAW) the format in FAR Subpart 12.6, as supplemented with additional information included in this notice.� This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.� This is a request for proposal (RFP) for commercial items IAW the procedures of FAR Part 12 � Acquisition of Commercial Items, in conjunction with FAR Part 15 � Contracting by Negotiation. This acquisition is issued as a Request for Proposal (RFP). This solicitation document incorporates provisions and clauses in effect through Federal Acquisition Circular FAC 2023-01, effective December 30, 2022.�� All questions regarding this solicitation, of a contractual nature or technical nature, shall be submitted in writing and sent via email to the Contract Specialist (Nikola.Zuber@fda.hhs.gov), by no later than 12:00 PM Eastern Time, on 3/23/2023. The Government may not consider questions received after this date and time. The email subject line shall read: FDA-RFP-75F40122R00067. It is the Offeror�s responsibility to confirm receipt of all proposals and/or questions by the closing date of this announcement by contacting the above Contract Specialist/Contracting Officer. It is the FDA�s intent to award an indefinite delivery-indefinite quantity (IDIQ) contract, with a performance period of five (5) years. The Government anticipates awarding an single award IDIQ contract with a ceiling of $20,000,000.00. These is no minimum or maximum number of delivery orders/task orders set for this IDIQ. IDIQ Minimum: The minimum guarantee for this IDIQ contract is $2,500.00, which will be obligated through a separate Task Order following the IDIQ award. IDIQ Maximum: The maximum aggregate dollar value of all task orders awarded over the 5-year ordering period of this IDIQ shall not exceed the IDIQ ceiling amount of $20,000,000.00. It is anticipated that a single-award Indefinite Delivery-Indefinite Quantity (IDIQ) type Contract, per FAR 16.5, will be awarded as a result of this solicitation.� Authorized contract types under this IDIQ contract are: Labor-Hour (LH), Time-and-Materials (T&M), Firm-Fixed-Price (FFP) or a combination thereof. See attached documentation for all information regarding this combined synopsis/solicitation posting.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/96a4ffade429438ca16cfad606e10f10/view)
- Place of Performance
- Address: Silver Spring, MD 20993, USA
- Zip Code: 20993
- Country: USA
- Zip Code: 20993
- Record
- SN06635039-F 20230401/230330230108 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |